Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older | Synapse
June 14, 2018Open Access
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
Key Points
To understand the mutation spectrum in elderly patients with acute myeloid leukemia and its clinical implications.
Analyzed genetic mutations in intensively treated patients aged 75 years or older.
Part of the AMLCG-1999 trial (NCT00266136).
Identified mutations as novel markers for chemorefractory disease.
Found correlations between specific mutations and inferior prognosis.
Abstract
mutations as a novel marker for chemorefractory disease and inferior prognosis. (AMLCG-1999 trial: clinicaltrials.gov identifier, NCT00266136).